Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

dual-target

dual-target is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 3
Pipeline programs 2
News articles 0
Drug details — dual-target
Class
—
Route
—
Patents
3
Programs
2
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

dual-target is an FDA-listed pharmaceutical active ingredient.

Key facts

INN dual-target

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. TARGET protocol EN 1.5 kcal/mL Phase 3 · Zealand Pharma · Critical Illness
  2. Target CD7 CAR-T cells Phase 1 · Chinese Academy of · T-cell Acute Lymphoblastic Leukemia

Related patents

Browse patents

  1. US 12145974

    Dual-target fusion proteins comprising FGF21 and GLP-1, connected through a Fc portion of an immunoglobulin

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9187746

    Dual targeting siRNA agents

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8629119

    Dual targeting of MIR-208 and MIR-499 in the treatment of cardiac disorders

    Expires Mon Jan 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is dual-target?

dual-target is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.